{"id":"W4225994592","doi":"10.1016/j.jtocrr.2022.100324","title":"Clinical Outcomes With Dabrafenib Plus Trametinib in a Clinical Trial Versus Real-World Standard of Care in Patients With BRAF-Mutated Advanced NSCLC","year":2022,"lang":"en","type":"article","venue":"JTO Clinical and Research Reports","topic":"Melanoma and MAPK Pathways","field":"Biochemistry, Genetics and Molecular Biology","cited_by":20,"is_retracted":false,"has_abstract":true,"ca_institutions":"University of British Columbia","funders":"Merck Sharp and Dohme; Roche; Novartis; Amgen; Pfizer; Les Laboratories Pierre Fabre; Novartis Pharmaceuticals Corporation; AstraZeneca; Takeda Pharmaceutical Company; Eli Lilly and Company; Bristol-Myers Squibb","keywords":"Dabrafenib; Hazard ratio; Medicine; Trametinib; Internal medicine; Oncology; Confidence interval; Proportional hazards model; Vemurafenib; Cancer","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00411096,0.0009735868,0.001604777,0.0003416367,0.0002862943,0.00127452,0.0006113718,0.001055529,0.001982264],"category_scores_gemma":[0.003870459,0.0003097072,0.002491929,0.0003156021,0.0007685804,0.0009575297,0.0004324791,0.00186032,0.0002726293],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.001376839,"about_ca_system_score_gemma":0.001064805,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0005230411,"about_ca_topic_score_gemma":0.001284898,"domain_scores_codex":[0.9980591,0.001271024,0.0001558697,0.000245954,0.0001204107,0.0001475829],"domain_scores_gemma":[0.998405,0.0004021381,0.0005310907,0.0001111747,0.0001123929,0.0004382644],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","study_design_scores_codex":[0.9648887,0.004338646,0.004037527,0.0005162196,0.002453786,0.0000359746,0.00005170072,0.001751348,0.001184384,0.0001166676,0.0003835754,0.02024141],"study_design_scores_gemma":[0.7297904,0.2375709,0.02408056,0.000124922,0.002642281,0.0001461915,0.00006855882,0.003025631,0.0008672936,0.0004007738,0.001239863,0.00004250168],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9942684,0.003187392,0.0002532406,0.0004827832,0.0002419049,0.0006001479,0.0002494987,0.00001844055,0.0006980898],"genre_scores_gemma":[0.9975,0.0006628746,0.0003425557,0.0001995246,0.0001208974,0.0005583772,0.0002927247,0.000002734374,0.0003203778],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.00411096,"threshold_uncertainty_score":0.02174109,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.07276526832441786,"score_gpt":0.4439244341244604,"score_spread":0.3711591658000425,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}